W. Martin C. Klop

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 357 citations · Full text

Medicine, Oncology, Surgery +17

The impact of nutritional status on the prognoses of patients with advanced head and neck cancer

M.A.E. de van der Schueren, Paul A.M. van Leeuwen, Dirk J. Kuik et al. · Cancer · 1999 · 338 citations

Agriculture, Nutrition, Oncology +16

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 337 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman et al. · Nature Communications · 2021 · 336 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17